NOT-NS-16-032: Notice of Participation of NINDS in PAR-16-246 "Neural Regulation of Cancer (R21)"

Notice of Participation of NINDS in PAR-16-246 "Neural Regulation of Cancer (R21)"

Notice Number: NOT-NS-16-032

Key Dates
Release Date: June 14, 2016

Related Announcements
PAR-16-246

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this announcement is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) will participate, effective immediately, in PAR-16-246 "Neural Regulation of Cancer (R21)"

The following changes and updates are made to PAR-16-246 to reflect participation of NINDS in this FOA:

Part 1. Overview Information

Components of Participating Organizations
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.396, 93.853

Funding Opportunity Purpose
Central nervous system (CNS) tumor studies are also encouraged, in addition to non-central nervous system activities. Language in the rest of the FOA is inclusive of CNS-related tumor studies.

Part 2. Section I. Funding Opportunity Description

Research Scope

NINDS

The National Institute of Neurological Disorders and Stroke (NINDS) has a shared interest with NCI in studies that involve primary (non-metastatic) brain or spinal cord tumors and their interactions with nerves, neuropeptides, neurotransmitters, and axon guidance molecules within the Central Nervous System (CNS). NINDS is supportive of applications focused on the Specific Challenges outlined in the PAR as long as the proposed activity is focused on a primary brain and/or spinal cord tumor(s). The overall goal is to encourage applications at the intersection between cancer biology and neuroscience, involving investigators with transdisciplinary expertise, to further our understanding of how nerves can influence tumor development, growth, or invasion within the CNS. Applications that propose to look at the impact of tumors on normal neuronal function are also encouraged. Lastly, NINDS also supports the involvement of neuroscientists with peripheral nervous system expertise in applications involving non-CNS cancers although these applications will be assigned to NCI as noted in the current PAR.

NINDS will not consider funding research activities in the following areas under this FOA:

Chemobrain, cognitive, or psycho-behavioral outcomes related to cancer treatment
Chemotherapy-induced peripheral neuropathy (CIPN)
Neuroendocrine cancers

Note: NINDS does not support the conduct of clinical trials under this FOA.

Part 2. Section VII. Agency Contacts

With participation of NINDS, the following contacts are added to the FOA.

Scientific Research Contact(s)

Jane W. Fountain, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS), NIH
Telephone 301-496-1431
Email: [email protected]

(for questions on NINDS submissions related to primary (non-metastatic) brain tumors)

Financial/Grants Management Contact(s)
Tijuana Decoster, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS), NIH
Telephone 301-496-9531
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Jane W. Fountain, Ph.D.
National Institute of Neurological Disorders and Stroke
Telephone: 301 496-1431
Email: [email protected]